Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience

✍ Scribed by Rothe, A.; Sasse, S.; Goergen, H.; Eichenauer, D. A.; Lohri, A.; Jager, U.; Bangard, C.; Boll, B.; von Bergwelt Baildon, M.; Theurich, S.; Borchmann, P.; Engert, A.

• Book ID: 124073590
• Publisher: American Society of Hematology
• Year: 2012
• Tongue: English
• Weight: 76 KB
• Volume: 120
• Category: Article
• ISSN: 0006-4971
• DOI: 10.1182/blood-2012-05-430918